Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
rgp120/HIV-1IIIB · 1 trial · 1 indication
| Name | Type | Description |
|---|---|---|
| rgp120/HIV-1IIIB | BIOLOGICAL | - |
Inclusion Criteria Patients must have the following: * Stage 1 or 2 Walter Reed clinical staging of HIV infected individuals. * The ability to understand and sign a written informed consent form, which must be obtained prior to study entry. * Be available for 24 weeks so that follow up may be comp...
Top 19 of 30 competitors
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Pfizer Inc. | PFE | 7 | PHASE3 | VLA15, Prevenar 20, 13vPnC, ATM-AVI, PG4 |
| Sanofi SA Sponsored ADR | SNY | 1 | PHASE3 | PCV21 |
| GSK plc Sponsored ADR | GSK | 4 | PHASE2 | Penmenvy, iNTS-TCV, Strep A vaccine, Pan-Salmonella vaccine |
| Grifols, S.A. Sponsored ADR Class B | GRFS | 1 | PHASE3 | Xembify |
| CorMedix Inc. | CRMD | 1 | PHASE3 | DefenCath |
| Sinovac Biotech Ltd. | SVA | 4 | PHASE3 | Sinovac PCV24, Group ACYW135X Meningococcal Conjugate Vaccine, Group ACYW135 Meningococcal Conjugate Vaccine |
| Novartis AG Sponsored ADR | NVS | 2 | PHASE2 | EDI048 |
| Innoviva, Inc. | INVA | 3 | PHASE2 | Eravacycline, Sulbactam-durlobactam |
| BiomX Inc. | PHGE | 1 | PHASE2 | BX004 |
| Hoffmann-La Roche | RHHBY | 1 | PHASE3 | Baloxavir Marboxil |
| Merck & Co., Inc. | MRK | 2 | PHASE1 | V118C |
| AstraZeneca PLC | AZN | 1 | PHASE1 | AZD7760 |
| BioNTech SE Sponsored ADR | BNTX | 1 | PHASE1 | BNT163 |
| 60 Degrees Pharmaceuticals, Inc. | SXTP | 1 | PHASE2 | Tafenoquine |
| Tarsus Pharmaceuticals, Inc. | TARS | 1 | PHASE2 | TP-05 |
| Moderna, Inc. | MRNA | 1 | PHASE2 | mRNA-1982 |
| AN2 Therapeutics, Inc. | ANTX | 1 | PHASE2 | Epetraborole |
| Emergent BioSolutions Inc. | EBS | 4 | - | AIGIV/kg |
| Phathom Pharmaceuticals, Inc. | PHAT | 1 | - | Vonoprazan |
rgp120/HIV-1IIIB is an investigational monoclonal antibody being studied for HIV Infections. It is being developed as a vaccine for HIV-1 seropositive adult volunteers. The drug is in Phase 1 clinical development and is not yet approved for any use.
rgp120/HIV-1IIIB is a monoclonal antibody designed to target the HIV-1 virus. It is being studied for its safety and immunogenicity in HIV-1 seropositive adults, meaning it is intended to provoke an immune response against the virus.
rgp120/HIV-1IIIB is being developed by Roche Holding AG, which trades under the ticker RHHBY. The company is conducting clinical research on this investigational monoclonal antibody for the treatment of HIV Infections.
rgp120/HIV-1IIIB is in Phase 1 clinical development. It is an investigational drug and has not been approved by regulatory authorities. One Phase 1 trial has been completed, and the drug remains in early-stage clinical research.
rgp120/HIV-1IIIB has one completed clinical trial, NCT00001992, titled 'A Phase I Study of the Safety and Immunogenicity of Rgp 120/HIV-1IIIB Vaccine in HIV-1 Seropositive Adult Volunteers.' This trial was conducted in the United States and enrolled adults aged 18 years and older.